Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials

American Journal of Gastroenterology

Volumn 91, Issue 4, 1996, Pages 660-673

  Veldhuyzen Van Zanten, Sander J O ^a   Cleary, Cynthia ^b   Talley, Nicolas J ^b   Peterson, Theresa C ^b   Nyrén, Olaf ^b   Bradley, Lawrence A ^b   Verlinden, Marleen ^b   Tytgat, Guido N J ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIULCER AGENT; BISMUTH CITRATE; CIMETIDINE; CISAPRIDE; DOMPERIDONE; FURAZOLIDONE; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; MISOPROSTOL; NITROFURANTOIN; PIRENZEPINE; PLACEBO; PROKINETIC AGENT; RANITIDINE; SUCRALFATE; SULPIRIDE; TRIMEBUTINE;

ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; GASTROINTESTINAL DISEASE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0029873337     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. Drossman DA, Thompson G, Talley NJ, et al. Identification of subgroups of functional gastrointestinal disorders. Gastroenterol Int 1991;4:145-60.
2. Talley NJ, Phillips SF. Non-ulcer dyspepsia: Potential causes and pathophysiology. Ann Intern Med 1988;108:865-79.
3. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-77.
4. Nyrén O, Lindberg G, Lindstrom E, et al. Economic costs of functional dyspepsia. In: PharmacoEconomics. Langhorne, PA: Adis International, Ltd., 1992: 312-24.
5. Nyrén O. Functional dyspepsia: Is gastric acid and/or Helicobacter pylori infection involved in the aetiology? Eur J Gastroenterol Hepatol 1992;4:608-14.
6. Veldhuyzen van Zanten SJO, Tytgat KMAJ, Jalali S, et al. Can gastritis symptoms be evaluated in clinical trials? An overview of treatment of gastritis, non-ulcer dyspepsia and Campylobacter-associated gastritis. J Clin Gastroenterol 1989;11:496-501.
7. Dobrilla G, Comberlato, Steele A, et al. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989;11:169-77.
8. Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991;26(S182):47-60.
9. Poynard T, Mory B, Levoir D, et al. Randomized clinical trials in patients with dyspepsia. In: Galmiche JP, Jian R, Mignon M, et al., eds. Non-ulcer dyspepsia. Pathophysiology and therapeutic approaches. London: John Libbey and Company, 1991: 227-38.
10. Rösch W. Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1989;24(S165):54-8.
11. Creytens G. Effect of the non-antidopamergic drug cisapride on postprandial nausea. Curr Ther Res 1984;36:1063-70.
12. Milo R. Non-cholinergic, non-antidopaminergic treatment of chronic digestive symptoms suggestive of a motility disorder. A two step pilot evaluation of cisapride. Curr Ther Res 1984;36:1053-62.
13. Corinaldesi R, Stanghellini V, Raiti C, et al. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987;28:300-5.
14. Testoni PA, Bagnolo F, Fanti L, et al. Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990;31:286-90.
15. Tatsuta M, Iishi H, Nakaizumi A, et al. Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1992;6:221-8.
16. Arts E, Anthoni H, de Roy G, et al. Domperidone in the treatment of dyspepsia: A double-blind placebo-controlled study. J Int Med Res 1979;7:158-61.
17. Agorastos I, Zissis N, Kaprinis I, et al. Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders. J Int Med Res 1981;9:143-7.
18. Nagler J, Miskovitz P. Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. Am J Gastroenterol 1981;76:495-9.
19. Davis R, Clench M, Mathias J. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: A double-blind, placebo-controlled study. Dig Dis Sci 1988;33:1505-11.
20. Perkel M, Morre C, Hersh T, et al. Metoclopramide therapy in patients with delayed gastric emptying. A randomized, double-blind study. Dig Dis Sci 1979;24:662-6.
21. Johannessen T, Petersen H, Kristensen P, et al. Cimetidine on-demand in dyspepsia. Experience with randomized controlled single-subject trials. Scand J Gastroenterol 1992;27:189-95.
22. Bates S, Sjöden P, Fellenius J, et al. Blocked and nonblocked acid secretion and reported pain in ulcer, nonulcer dyspepsia, and normal subjects. Gastroenterology 1989;97:376-83.
23. Funch-Jensen P, Skoubo-Kristensen E, Kruse A, et al. Sucralfate in gastritis. Scand J Gastroenterol 1987;22(S127):93-6.
24. Kagan G, Huddlestone L, Wolstencroft P. Comparison of dicyclomine with antacid and without antacid in dyspepsia. J Int Med Res 1984;12:174-8.
25. Berstad A, Alexander B, Weberg R, et al. Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. Gastroenterology 1988;95:619-24.
26. McNulty C, Gearty J, Crump B, et al. Campylobacter pyloridis and associated gastritis: Investigator blind, placebo-controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 1986; 293:645-9.
27. Patchett S, Beattie S, Leen E, et al. Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. Br Med J 1991;303:1238-40.
28. Rauws E, Langenberg W, Houthoff H, et al. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988;94:33-40.
29. Westblom TU, Madan E, Subik MA, et al. Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection. Scand J Gastroenterol 1992;27:249-52.
30. Stene-Larsen G, Nesland A, Berstad A. Follow-up study of erosive prepyloric changes. Scand J Gastroenterol 1989;24:430-3.
31. Deruyttere M, Lepoutre L, Heylen H, et al. Cisapride in the management of chronic functional dyspepsia: A multicenter, double-blind, placebo-controlled study. Clin Ther 1987;10:44-51.
32. François J, De Nutte N. Nonulcer dyspepsia: Effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987;41:891-8.
33. Goethals C, Van de Mierop L. Cisapride in the treatment of chronic functional dyspepsia. Results of a double-blind placebo-controlled crossover study. Curr Ther Res 1987;42:261-7.
34. Hannon R. Efficacy of cisapride in patients with nonulcer dyspepsia. A placebo-controlled study. Curr Ther Res 1987;42:814-22.
35. Rösch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987;22:161-4.
36. De Nutte N, Van Ganse W, Witterhulghe M, et al. Relief of epigastric pain in nonulcer dyspepsia: Controlled trial of the promotility drug cisapride. Clin Ther 1989;11:62-8.
37. Jian R, Ducrot F, Ruskoné A, et al. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia: A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34:657-64.
38. Hausken T, Berstad A. Cisapride treatment of patients with nonulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo controlled trial. Scand J Gastroenterol 1992;27:213-7.
39. Hausken T, Berstad A. Wide gastric antrum with non-ulcer dyspepsia. Effect of cisapride. Scand J Gastroenterol 1992;27:427-32.
40. Van Ganse W, Van Damme L, Van de Mierop L, et al. Chronic dyspepsia: Double-blind treatment with domperidone (R 33 812) or a placebo. A multicentre therapeutic evaluation. Curr Ther Res 1978; 23:695-701.
41. Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J 1979;55(S1):30-2.
42. DeLoose F. Domperidone in chronic dyspepsia: A pilot open study and a multicentre general practice cross-over comparison with metoclopramide and placebo. Pharmatherapeutica 1979;2:140-6.
43. Englert W, Schlich D. A double-blind crossover trial of domperidone in chronic postprandial dyspepsia. Postgrad Med J 1979;51:28-9.
44. Haarmann K, Lebkuchner F, Widmann A, et al. A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress. Postgrad Med J 1979;55(S1): 24-7.
45. Van de Mierop L, Rutgeerts L, Van den Langenbergh B, et al. Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation. Digestion 1979;19:244-50.
46. Sarin SK, Sharma P, Chawla YK, et al. Clinical trial on the effect of domperidone on non-ulcer dyspepsia. Indian J Med Res 1986;83: 623-8.
47. Johnson A. Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. Br Med J 1971;2:25-6.
48. LaBrooy S, Lovell D, Misiewicz J. The treatment of non-ulcer dyspepsia. In: Wastell C, Lance P, eds. Cimetidine. The Westminster Hospital symposium. London: Churchill Livingstone, 1978: 131-40.
49. MacKinnon M, Willing RL, Whitehead R. Cimetidine in the management of symptomatic patients with duodenitis. A double-blind controlled trial. Dig Dis Sci 1982;27:217-9.
50. Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res 1985;37:980-91.
51. Kelbaek H, Linde J, Eriksen J, et al. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand 1985;217:281-7.
52. Kleveland PM, Larsen S, Sandvik L, et al. The effect of cimetidine in non-ulcer dyspepsia. Experience with a multi-cross-over model. Scand J Gastroenterol 1985;20:19-24.
53. Nesland A, Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985;20:629-35.
54. Lance P, Wastell C, Schiller K. A controlled trial of cimetidine for the treatment of nonulcer dyspepsia. J Clin Gastroenterol 1986;8:414-8.
55. Nyren O, Adami HO, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986;314:339-43.
56. Talley NJ, McNeil D, Hayden A, et al. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986;91:149-56.
57. Gotthard R, Bodemar G, Brodin U, et al. Treatment with cimetidine, antacids, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988;23:7-18.
58. Johannessen T, Fjosne U, Kleveland P, et al. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988;23:327-36.
59. Singal AK, Kumar A, Broor SL. Cimetidine in the treatment of non-ulcer dyspepsia: Results of a randomized double-blind, placebo controlled study. Curr Med Res Opin 1989;11:390-7.
60. Johannessen T, Kristensen P, Petersen H, et al. The symptomatic effect of 1-day treatment periods with cimetidine in dyspepsia. Combined results from randomized, controlled, single-subject trials. Scand J Gastroenterol 1991;26:974-80.
61. Olubuyide I, Ayoola E, Okubanjo A, et al. Non-ulcer dyspepsia in Nigerians: Clinical and therapeutic results. Scand J Gastroenterol 1986;21(S124):83-7.
62. Saunders J, Oliver R, Higson D. Dyspepsia: Incidence of non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J 1986;292:665-8.
63. Farup P, Larsen S, Ulshagen K, et al. Ranitidine for non-ulcer dyspepsia. A clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment. Scand J Gastroenterol 1991;26:1209-16.
64. Dal Monte P, D'Imperio N, Accardo P, et al. Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial. Scand J Gastroenterol 1983;17(S72):247-50.
65. Hradsky M, Wikander M. Effect of pirenzipine in the treatment of non-ulcer dyspepsia. A double-blind study. Scand J Gastroenterol 1983;17(S72):251-2.
66. Weberg R, Berstad A. Low-dose antacids and pirenzipine in the treatment of patients with nonulcer dyspepsia and erosive prepyloric changes. A randomized, double-blind, placebo-controlled trial. Scand J Gastroenterol 1988;23:237-43.
67. Gad A, Dobrilla G. Campylobacter pylori and non-ulcer dyspepsia. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy. Scand J Gastroenterol 1989;24(S167):39-43.
68. Smith PM, Troughton AH, Gleeson F, et al. Pirenzepine in non-ulcer dyspepsia: A double-blind multicentre trial. J Int Med Res 1990;18: 16-20.
69. Kairaluoma M, Hentilae R, Alavaikko M, et al. Sucralfate versus placebo in treatment of non-ulcer dyspepsia. Am J Med 1987; 83(S3B):51-5.
70. Skoubo-Kristensen E, Funch-Jensen P, Kruse A, et al. Controlled clinical trial with sucralfate in the treatment of macroscopic gastritis. Scand J Gastroenterol 1989;24:716-20.
71. Hausken T, Stene-Larsen G, Lange O, et al. Misoprostol treatment exacerbates abdominal discomfort in patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled, multicentre study. Scand J Gastroenterol 1990;25:1028-33.
72. R in the management of gastritis and duodenitis. A double-blind, placebo-controlled clinical trial. J Int Med Res 1984;12:51-5.
73. Kleveland PM, Johannessen T, Kristensen P, et al. Effect of pancreatic enzymes in non-ulcer dyspepsia. A pilot study. Scand J Gastroenterol 1990;25:298-301.
74. Hui WM, Lam SK, Lok ASF, et al. Sulpiride improves functional dyspepsia: A double-blind controlled study. J Gastroenterol Hepatol 1986;1:391-9.
75. Walters JM, Crean P, McCarthy CF. Trimebutine, a new antispasmodic in the treatment of dyspepsia. Irish J Med 1980;73:380-1.
76. Rokkas T, Pursey C, Uzoechina E, et al. Non-ulcer dyspepsia and short term De-Nol therapy: A placebo-controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988;29:1386-91.
77. Lambert J, Dunn K, Borromeo M, et al. Campylobacter pylori: A role in non-ulcer dyspepsia. Scand J Gastroenterol 1989;24(S160):7-13.
78. Loffeld RJ, Potters HV, Stobberingh E, et al. Campylobacter-associated gastritis in patients with non-ulcer dyspepsia: A double-blind, placebo-controlled trial with colloidal bismuth subcitrate. Gut 1989; 30:1206-12.
79. Kang J, Tay H, Wee A, et al. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double-blind, placebo-controlled study. Gut 1990;31:476-80.
80. Goh KL, Parasakthi N, Peh SC, et al. Helicobacter pylori infection and non-ulcer dyspepsia: The effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol 1991;26:1123-31.
81. Glupczynski Y, Burette A, Labbe M, et al. Campylobacter pylori-associated gastritis: A double-blind, placebo-controlled trial with amoxycillin. Am J Gastroenterol 1988;83:365-72.
82. Morgan D, Kraft W, Bender M, et al. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. Gastroenterology 1988;95:1178-84.
83. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 1994;106:1174-83.
84. Veldhuyzen van Zanten SJO. A systematic overview (meta-analysis) of outcome measures in patients with Helicobacter pylori gastritis trials and functional dyspepsia. J Clin Epidemiol 1993;46:273-9.
85. Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-60.
86. Heading RC. Definitions of dyspepsia. Scand J Gastroenterol 1991; 26(Suppl 182):1-6.
87. Klein KB. Controlled trials in the irritable bowel syndrome: A critique. Gastroenterology 1988;95:232-41.
88. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature: A comparison of MEDLARS and manual methods. Control Clin Trials 1985;6:271-9.
89. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: A population-based study. Gastroenterology 1992; 102:1259-68.
90. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4.
91. Talley NJ, Philips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990;31:77-81.
92. Talley NJ, Piper DW. The association between non-ulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 1985;20: 896-900.
93. Working Party Report. Management of dyspepsia. Lancet 1988:i: 576-9.
94. Barbara L, Camilleri M, Corinaldesi R, et al. Definition and investigation of dyspepsia. Dig Dis Sci 1989;34:1272-6.
95. Klauser G, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastroesophageal disease. Lancet 1990;335:205-8.
96. Greenlaw R, Sheahan DG, DeLuca V, et al. Gastroduodenitis: A broader concept of peptic ulcer disease. Dig Dis Sci 1980;25:660-72.
97. Cotton PB, Price AB, Tighe JR, et al. Preliminary evaluation of "duodenitis" by endoscopy and biopsy. Br Med J 1973;3:430-3.
98. McCallum RW, Singh D, Wollman J. Endoscopic and histologic correlations of the duodenal bulb. Arch Pathol Lab Med 1979;103: 169-72.
99. Elta GH, Appelman HD, Beheler EM, et al. A study of the correlation between endoscopic and histologic diagnoses in gastroduodenitis. Am J Gastroenterol 1987;82:749-53.
100. Taor RE, Fox B, Ware J, et al. Gastritis: Gastroscopic and microscopic. Endoscopy 1975;7:209-15.
101. Sauerbruch T, Schreiber MA, Schussler P, et al. Endoscopy in the diagnosis of gastritis. Diagnostic value of endoscopic criteria in relation to histological diagnosis. Endoscopy 1984;16:101-4.
102. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965;21:467-80.
103. Willan AR, Pater JL. Carryover and the two-period crossover design. Biometrics 1986;42:593-9.
104. Louis TA, Lavori PW, Bailor JC, et al. Crossover and self-controlled designs in clinical research. N Engl J Med 1984;310:24-31.
105. Day S. Controlled trials in single subjects. Br Med J 1991;303:522.
106. Lewis JA. Controlled trials in single subjects. Limitations of use. Br Med J 1991;303:173-6.
107. Altman D. Randomization. Br Med J 1991;302:1481-2.
108. Knill-Jones RP. A formal approach to symptoms in dyspepsia. Clin Gastroenterol 1985;14:517-29.
109. Talley NJ, Nyren O, Drossman DA, et al. Functional gastrointestinal disorders: Toward optimal design of controlled treatment trials, with special reference to the irritable bowel syndrome. Gastroenterol Int 1993;6:189-211.
110. Guyatt GH, Townsend M, Berman LB, et al. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 1987;40:1129-33.
111. Kirschner B, Guyatt GH. A methodologic framework for assessing health indices. J Chronic Dis 1985;38:27-30.
112. Turk DC, Kerns RD. Conceptual issues in the assessment of clinical pain. Int J Psychiatry 1983;13:57-68.
113. Melzack R. The McGill Pain Questionnaire. Pain 1987;30:191-7.
114. Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 1985;23:345-6.
115. Sjöden PO, Bates S, Nyrén O. Continuous self-recording of epigastric pain with two rating scales: Compliance, authenticity, reliability and sensitivity. J Behav Assess 1983;5:327-34.
116. Nyrén O, Adami HO, Bates S, et al. Self-rating of pain in nonulcer dyspepsia. J Clin Gastroenterol 1987;9:408-14.
117. Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as outcome measures in trials of non-ulcer dyspepsia and Helicobacter pylori? J Clin Epidemiol 1993; 46:273-9.
118. Dimenäs E, Glise H, Hallerbäck B, et al. Quality of Life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens. Scand J Gastroenterol 1993;28:681-7.
119. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84.
120. Godfrey K. Comparing the means of several groups. N Engl J Med 1985;313:1450-6.
121. Games PA, Keselman HJ, Rogan JC. A review of simultaneous pairwise multiple comparisons. Stat Neerland 1983;37:53-8.
122. Talley NJ, Jones M, Piper DW. Psychosocial and childhood factors in essential dyspepsia. Scand J Gastroenterol 1988;23:341-6.
123. Richter JE. Stress psychologic and environmental factors in functional dyspepsia. Scand J Gastroenterol 1991;26(Suppl 182):40-6.
124. Drossman DA. Psychosocial factors in functional dyspepsia. Eur J Gastroenterol Hepatol 1992;4:602-7.
125. Guyatt GH, Bombardier C, Tugwell P. Measuring disease specific quality of life in clinical trials. Can Med Assoc J 1986;134:889-95.
126. Guyatt GH, Veldhuyzen van Zanten SJO, Feeney DH, et al. Measuring quality of life in clinical trials. A taxonomy and review. Can Med J Assoc 1989;140:1441-8.
127. Abell TL, Cutts TF, Cooper T. Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life. Scand J Gastroenterol 1993;28(Suppl 195):60-4.
128. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306-10.
129. Derogatis LR. The Psychosocial Adjustment to Illness Scale (PAIS). J Psychosom Res 1986;30:77-91.
130. Wilhelmsen I, Bakke A, Tangen Haug T, et al. Psychosocial Adjustment to Illness Scale (PAIS-SR) in a Norwegian Material of patients with functional dyspepsia, duodenal ulcer, and urinary bladder dysfunction. Clinical validation of the instrument. Scand J Gastroenterol 1994;29:611-7.
131. Talley NJ, McNeil D, Hayden A, et al. Prognosis of chronic unexplained dyspepsia. A prospective study of potential predictor variables in patients with endoscopically diagnosed nonulcer dyspepsia. Gastroenterology 1987;92:1060-6.